 |
3P BIOPHARMACEUTICALS |
CRO / CMO |
API/IMP process development and GMP manufacturing |
5RTM |
API/IMP process development and GMP manufacturing
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Biologics production: New Biological Entities (mAbs, vaccines, fusion proteins) and Biosimilars/Biobetters from microbial fermentation and mammalian cell culture |
5RTM |
Biologics production: New Biological Entities (mAbs, vaccines, fusion proteins) and Biosimilars/Biobetters from microbial fermentation and mammalian cell culture
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Development of API formulation |
5RTM |
Development of API formulation
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Stability Studies (API/IMP/Cell banks) |
5RTM |
Stability Studies (API/IMP/Cell banks)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP Cell Bank Manufacturing (MCB/WCB/EPCB) and storage |
5RTM |
GMP Cell Bank Manufacturing (MCB/WCB/EPCB) and storage
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP production (fermenters up to 1000L and Bioreactors up to 400L) for Clinical trials and Commercial stage |
5RTM |
GMP production (fermenters up to 1000L and Bioreactors up to 400L) for Clinical trials and Commercial stage
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Scale up and No GMP production for Preclinical studies |
5RTM |
Scale up and No GMP production for Preclinical studies
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Analytics development and validation platform (API, IMP, IPC) for Biosimilars |
5RTM |
Analytics development and validation platform (API, IMP, IPC) for Biosimilars
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Analytics development and validation platform (API, IMP, IPC) for New biological entities |
5RTM |
Analytics development and validation platform (API, IMP, IPC) for New biological entities
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Bioprocess Development/Optimization Platform (USP/DSP) |
5RTM |
Bioprocess Development/Optimization Platform (USP/DSP)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Freedom-to-operate platform in Bacteria, yeast and mammalian |
5RTM |
Freedom-to-operate platform in Bacteria, yeast and mammalian
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Production of advanced Therapy Medicinal Products |
5RTM |
Production of advanced Therapy Medicinal Products
Type:
CRO / CMO
|
 |
ADL Bionatur Solutions |
CRO / CMO |
Splittera application for gene therapy. It allows in-vivo covalent reconstitution of large proteins. Already licensed for retinal chronic disorders. Available for other fields and diseases. |
5RTM |
Splittera application for gene therapy. It allows in-vivo covalent reconstitution of large proteins. Already licensed for retinal chronic disorders. Available for other fields and diseases.
Type:
CRO / CMO
|
|
ADL Bionatur Solutions |
CRO / CMO
Screening |
Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies. |
5RTM |
Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies.
Type:
CRO / CMO
Screening
|
|
ADL Bionatur Solutions |
Drug Delivery |
Zip's "Zera" platform for normalization of the immune response raised by recombinant vaccines, DNA/RNA vaccines. Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery. |
3CV |
Zip's "Zera" platform for normalization of the immune response raised by recombinant vaccines, DNA/RNA vaccines. Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery.
Type:
Drug Delivery
|
 |
ADM BIOPOLIS |
CRO / CMO
Screening |
Novel functional probiotics screening, validation and production |
1R+D |
Novel functional probiotics screening, validation and production
Type:
CRO / CMO
Screening
|
|
ADM BIOPOLIS |
CRO / CMO |
Recombinant protein expression systems |
1R+D |
Recombinant protein expression systems
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO |
Contract manufacturing: upstream and downstream development, analytical development, scale-up |
5RTM |
Contract manufacturing: upstream and downstream development, analytical development, scale-up
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO |
Metagenomics and metabolomic analysis |
5RTM |
Metagenomics and metabolomic analysis
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO
Screening |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials |
5RTM |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials
Type:
CRO / CMO
Screening
|
 |
APTUS Biotech |
Drug Delivery
Enabling Technologies |
Aptamer selection and characterization |
5RTM |
Aptamer selection and characterization
Type:
Drug Delivery
Enabling Technologies
|
 |
BANCO ESPAÑOL DE ALGAS |
Enabling Technologies
Screening |
The BEA has fully-equipped laboratories (microscopes, flow cytometers, centrifuges, flow chambers, fluorimeters, water equipment, etc.) and activation chambers. It also has a culture plant and greenhouse of about 300 square meters fitted with culture syst |
1R+D |
The BEA has fully-equipped laboratories (microscopes, flow cytometers, centrifuges, flow chambers, fluorimeters, water equipment, etc.) and activation chambers. It also has a culture plant and greenhouse of about 300 square meters fitted with culture syst
Type:
Enabling Technologies
Screening
|
 |
Biobide |
CRO / CMO
Screening |
Zebrafish Efficacy Assays as well as target identification and validation assays for different therapeutic areas in drug discovery: neurodegenerative diseases, oncology, cardiovascular, immune system, infectious diseases, rare diseases (DMD, ALS...) |
5RTM |
Zebrafish Efficacy Assays as well as target identification and validation assays for different therapeutic areas in drug discovery: neurodegenerative diseases, oncology, cardiovascular, immune system, infectious diseases, rare diseases (DMD, ALS...)
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO
Screening |
Zebrafish disease models generation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemically induced models, xenograft models... |
5RTM |
Zebrafish disease models generation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemically induced models, xenograft models...
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO
Screening |
Zebrafish Toxicity screening assays for Pharma, Biotech, Chemical, Tobacco and Cosmetic companies for candidate selection in early discovery and development phases: developmental toxicity, neurotoxicity, cardiotoxicity, hepatotoxicity, ototoxicity, immuno |
5RTM |
Zebrafish Toxicity screening assays for Pharma, Biotech, Chemical, Tobacco and Cosmetic companies for candidate selection in early discovery and development phases: developmental toxicity, neurotoxicity, cardiotoxicity, hepatotoxicity, ototoxicity, immuno
Type:
CRO / CMO
Screening
|
 |
BIONET INGENIERÍA |
Enabling Technologies
Screening |
Labscale Tangential Flow Filtration units, very flexible for R&D since it allows the integration of all types of membranes: ceramic, hollow fiber and cassettes |
5RTM |
Labscale Tangential Flow Filtration units, very flexible for R&D since it allows the integration of all types of membranes: ceramic, hollow fiber and cassettes
Type:
Enabling Technologies
Screening
|
|
BIONET INGENIERÍA |
Enabling Technologies |
Smart functional modules to be coupled to bioreactor technologies in a Plug&Play fashion. Examples of these are the Continuous Process Modules for performance of continuous processing, and the bBreath module for the analysis of gas composition at the exha |
5RTM |
Smart functional modules to be coupled to bioreactor technologies in a Plug&Play fashion. Examples of these are the Continuous Process Modules for performance of continuous processing, and the bBreath module for the analysis of gas composition at the exha
Type:
Enabling Technologies
|
|
BIONET INGENIERÍA |
CRO / CMO
Enabling Technologies
Screening |
Glass labscale bioreactors |
5RTM |
Glass labscale bioreactors
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
CIBER |
Enabling Technologies
Others |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
1R+D |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
Enabling Technologies
Others
|
|
CIBER |
CRO / CMO
Enabling Technologies
Screening |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
2PreV |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
CIBER |
CRO / CMO
Enabling Technologies |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization |
2PreV |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization
Type:
CRO / CMO
Enabling Technologies
|
|
CIBER |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates |
5RTM |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates
Type:
CRO / CMO
Enabling Technologies
Others
|
|
CIBER |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides) |
5RTM |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides)
Type:
CRO / CMO
Enabling Technologies
Others
|
 |
ENTRECHEM |
Others |
Synthetic Biology for Human Health. Opening up the chemical space of complex bacterial natural products for oncology and immunosuppression applications |
2PreV |
Synthetic Biology for Human Health. Opening up the chemical space of complex bacterial natural products for oncology and immunosuppression applications
Type:
Others
|
 |
Enzymlogic |
CRO / CMO
Screening |
Development of an assay platform to perform binding kinetic profiling of GPCR agonist and antagonist in a HTS format |
1R+D |
Development of an assay platform to perform binding kinetic profiling of GPCR agonist and antagonist in a HTS format
Type:
CRO / CMO
Screening
|
|
Enzymlogic |
CRO / CMO
Screening |
Development of an assay platform to perform binding kinetic profiling of KINASE inhibitors in a HTS format |
1R+D |
Development of an assay platform to perform binding kinetic profiling of KINASE inhibitors in a HTS format
Type:
CRO / CMO
Screening
|
 |
FUND. PROGRESO Y SALUD |
CRO / CMO |
Computational Biologý and Bioinformatics Unit
Diagnostic Imaging Sevice
Flow Cytometry and Cell Separation Service
Genome and Sequencing Service
Multiple Uses Laboratory Service
Optical and Confocal Microscopy Service
Proteomic Service
Tissue, Cell |
1R+D |
Computational Biologý and Bioinformatics Unit
Diagnostic Imaging Sevice
Flow Cytometry and Cell Separation Service
Genome and Sequencing Service
Multiple Uses Laboratory Service
Optical and Confocal Microscopy Service
Proteomic Service
Tissue, Cell
Type:
CRO / CMO
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials |
3CV |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials
Type:
CRO / CMO
|
|
FUND. PROGRESO Y SALUD |
Enabling Technologies |
Hybridome/Antibody Production Platform |
1R+D |
Hybridome/Antibody Production Platform
Type:
Enabling Technologies
|
|
FUND. PROGRESO Y SALUD |
Screening |
Screening Cell lines & Animal Models |
1R+D |
Screening Cell lines & Animal Models
Type:
Screening
|
|
FUND. PROGRESO Y SALUD |
Drug Delivery |
Liposome delivery System (Prostate Cancer) |
1R+D |
Liposome delivery System (Prostate Cancer)
Type:
Drug Delivery
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank |
5RTM |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank
Type:
CRO / CMO
|
 |
Fundacion MEDINA |
CRO / CMO |
Bioanalytical Platform |
3CV |
Bioanalytical Platform
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput screening platform for drug discovery |
3CV |
High throughput screening platform for drug discovery
Type:
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Chemical Isolation & Structural Elucidation |
3CV |
Chemical Isolation & Structural Elucidation
Type:
CRO / CMO
|
|
Fundacion MEDINA |
CRO / CMO |
Microbial and Mammalian cell culturing |
3CV |
Microbial and Mammalian cell culturing
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput screening platform for drug discovery |
2PreV |
High throughput screening platform for drug discovery
Type:
Screening
|
|
Fundacion MEDINA |
Enabling Technologies
Screening |
Mass spectrometry metabolomics |
1R+D |
Mass spectrometry metabolomics
Type:
Enabling Technologies
Screening
|
|
Fundacion MEDINA |
Screening |
Microbial Natural Product Libraries |
3CV |
Microbial Natural Product Libraries
Type:
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Preclinical Safety Platform |
3CV |
Preclinical Safety Platform
Type:
CRO / CMO
|
 |
Histocell |
CRO / CMO |
Cell shipping medium. To develop ready-to-use cell based models for research |
5RTM |
Cell shipping medium. To develop ready-to-use cell based models for research
Type:
CRO / CMO
|
 |
IIS La Fe |
Screening |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour). |
2PreV |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour).
Type:
Screening
|
|
IIS La Fe |
Enabling Technologies |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions |
2PreV |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions
Type:
Enabling Technologies
|
|
IIS La Fe |
CRO / CMO
Drug Delivery |
Advanced Therapies Unit: offers services that require specially designed infrastructures under the most demanding regulatory framework for the development of pre-clinical and clinical studies within the Advanced Therapies programs. |
5RTM |
Advanced Therapies Unit: offers services that require specially designed infrastructures under the most demanding regulatory framework for the development of pre-clinical and clinical studies within the Advanced Therapies programs.
Type:
CRO / CMO
Drug Delivery
|
|
IIS La Fe |
CRO / CMO |
Clinical and Products with Biological Activity Research Unit (UICAB): Participates in the development of clinical studies aimed at different pathologies, providing healthcare support in highly complex studies, such as Clinical Trials in early phases |
5RTM |
Clinical and Products with Biological Activity Research Unit (UICAB): Participates in the development of clinical studies aimed at different pathologies, providing healthcare support in highly complex studies, such as Clinical Trials in early phases
Type:
CRO / CMO
|
|
IIS La Fe |
Enabling Technologies |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc. |
1R+D |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc.
Type:
Enabling Technologies
|
|
IIS La Fe |
Screening |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE) |
1R+D |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE)
Type:
Screening
|
|
IIS La Fe |
Screening |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform |
1R+D |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform
Type:
Screening
|
|
IIS La Fe |
Enabling Technologies
Screening |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening |
1R+D |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening
Type:
Enabling Technologies
Screening
|
|
IIS La Fe |
Screening |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques |
3CV |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques
Type:
Screening
|
|
IIS La Fe |
Enabling Technologies |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.) |
1R+D |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.)
Type:
Enabling Technologies
|
|
IIS La Fe |
|
Biolectronics, Signal Processing and Algorithmy Unit: provides support in the development of medical devices related to advanced signal processing, for the optimization of diagnostics and therapeutic applications. |
1R+D |
Biolectronics, Signal Processing and Algorithmy Unit: provides support in the development of medical devices related to advanced signal processing, for the optimization of diagnostics and therapeutic applications.
Type:
|
 |
IMMUNOSTEP |
Enabling Technologies |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems |
2PreV |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems
Type:
Enabling Technologies
|
 |
Integromics |
Screening |
Genomics Analysis for Personalized Medicine/Diagnosis |
1R+D |
Genomics Analysis for Personalized Medicine/Diagnosis
Type:
Screening
|
 |
IRYCIS |
Others
Screening |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response |
3CV |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response
Type:
Others
Screening
|
 |
Laminar Pharma |
Enabling Technologies |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism |
3CV |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism
Type:
Enabling Technologies
|
 |
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies |
METABOLOMICS & BIOANALYTICS:
Mass spectrometry,
Chromatography,
Bioinformatics |
3CV |
METABOLOMICS & BIOANALYTICS:
Mass spectrometry,
Chromatography,
Bioinformatics
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
|
|
Leitat |
CRO / CMO
Enabling Technologies
Screening |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient |
5RTM |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Enabling Technologies
Screening |
SKIN HEALTH & COSMETICS:
Safety
Beauty
Dermatology |
3CV |
SKIN HEALTH & COSMETICS:
Safety
Beauty
Dermatology
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
REGENERATIVE MEDICINE:
Pharmacology,
In vivo imaging,
Stem cell therapy,
Sports medicine,
Muscle and tendon in vivo models |
3CV |
REGENERATIVE MEDICINE:
Pharmacology,
In vivo imaging,
Stem cell therapy,
Sports medicine,
Muscle and tendon in vivo models
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells. |
5RTM |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells.
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab’)2, scFv, Conjugation, ELISA |
5RTM |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab’)2, scFv, Conjugation, ELISA
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
NUTRITION & FOOD SCIENCES:
Body barriers (skin, digestive,,,),
ADMEtox,
Energetic metabolism,
Microbiota |
3CV |
NUTRITION & FOOD SCIENCES:
Body barriers (skin, digestive,,,),
ADMEtox,
Energetic metabolism,
Microbiota
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Enabling Technologies
Screening |
Antibody & Protein Engineering Platform:
Cloning, Chimeric mAbs, Humanized mAbs, scFv fragments, Fusion proteins Modeling, Transient expression, Stable clones, Nanobodies, Bispecifics, ADCs, Production, Biosimilars |
5RTM |
Antibody & Protein Engineering Platform:
Cloning, Chimeric mAbs, Humanized mAbs, scFv fragments, Fusion proteins Modeling, Transient expression, Stable clones, Nanobodies, Bispecifics, ADCs, Production, Biosimilars
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
ONCOLOGY & ANGIOGENESIS:
Target discovery,
Drug Efficacy,
Drug development |
3CV |
ONCOLOGY & ANGIOGENESIS:
Target discovery,
Drug Efficacy,
Drug development
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
DIAGNOSIS & BIOSENSORS:
Biomarkers,
Theragnostics,
Remote sensing |
3CV |
DIAGNOSIS & BIOSENSORS:
Biomarkers,
Theragnostics,
Remote sensing
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
 |
Microomics Systems |
CRO / CMO
Enabling Technologies
Screening |
High quality metagenomics, genomics and transcriptomics services to companies industrial research centers in the fields of: pre and probiotics, metabolic studies, human and animal health, dental treatments and agriculture solutions (biofertilizers) |
5RTM |
High quality metagenomics, genomics and transcriptomics services to companies industrial research centers in the fields of: pre and probiotics, metabolic studies, human and animal health, dental treatments and agriculture solutions (biofertilizers)
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
NEURAL THERAPIES |
CRO / CMO |
Screening of molecules as neuroprotectors, mainly in cerebrovascular and Alzheimer diseases. Evaluation on infarct volume, behavioral responses, inflammation, homeostatic response and cell death.
Models: Focal ischemia, global ischemia, oxygen and OGD. |
1R+D |
Screening of molecules as neuroprotectors, mainly in cerebrovascular and Alzheimer diseases. Evaluation on infarct volume, behavioral responses, inflammation, homeostatic response and cell death.
Models: Focal ischemia, global ischemia, oxygen and OGD.
Type:
CRO / CMO
|
 |
OPERON |
Screening |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections |
3CV |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections
Type:
Screening
|
 |
OWL Metabolomics |
CRO / CMO |
Metabolomics provider for preclinical and clinical studies |
5RTM |
Metabolomics provider for preclinical and clinical studies
Type:
CRO / CMO
|
 |
StemTek Therapeutics |
Screening |
Drug screening / Discovery / validation on cancer stem cells, phenotypic HTS screening, secondary validation to in vivo efficacy testing |
5RTM |
Drug screening / Discovery / validation on cancer stem cells, phenotypic HTS screening, secondary validation to in vivo efficacy testing
Type:
Screening
|
 |
VIVEBIOTECH |
CRO / CMO |
Development of more cost-effective gene therapy processes |
3CV |
Development of more cost-effective gene therapy processes
Type:
CRO / CMO
|
|
VIVEBIOTECH |
CRO / CMO |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile. |
3CV |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile.
Type:
CRO / CMO
|
 |
Vivia Biotech |
CRO / CMO
Enabling Technologies
Screening |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations |
5RTM |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
ZeClinics |
CRO / CMO
Screening |
Discovery-preclinical safety services for drug discovery using zebrafish. ZeTox: acute, chronic, general and organ-specific toxicology tests. |
5RTM |
Discovery-preclinical safety services for drug discovery using zebrafish. ZeTox: acute, chronic, general and organ-specific toxicology tests.
Type:
CRO / CMO
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
Discovery-preclinical disease modeling services using zebrafish. ZeGenesis: generation of knock-out, knock-in, transgenics zebrafish or cell lines through CRISPR/Cas9. |
5RTM |
Discovery-preclinical disease modeling services using zebrafish. ZeGenesis: generation of knock-out, knock-in, transgenics zebrafish or cell lines through CRISPR/Cas9.
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
Discovery-preclinical services for drug efficacy using zebrafish. ZeEfficacy: early bioactivity evaluation of compound libraries with high-content phenotypical screenings. |
5RTM |
Discovery-preclinical services for drug efficacy using zebrafish. ZeEfficacy: early bioactivity evaluation of compound libraries with high-content phenotypical screenings.
Type:
CRO / CMO
Enabling Technologies
Screening
|